Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics

歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1477)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 24, 2022

The Board announces that all the resolutions as set out in the Notice were duly passed by the Shareholders as ordinary resolutions by way of poll at the Annual General Meeting.

The board of directors (the "Board") of Ocumension Therapeutics (the "Company") is pleased to announce the poll results of the annual general meeting of the Company (the "Annual General Meeting") held at Taishan Meeting Room, 5th Floor, Want Want Plaza, No. 211 Shimen Yi Road, Jing'an District, Shanghai, the People's Republic of China on Friday, June 24, 2022 at 10:00 a.m..

Reference is made to the Company's circular (the "Circular") in connection with the Annual General Meeting and notice of the Annual General Meeting (the "Notice") dated April 27, 2022. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting results in respect of the resolutions proposed at the Annual General Meeting were as follows:

			Number of Votes (%)				
			For	Against			
1.	Comp	ceive and adopt the audited consolidated financial statements of the any and its subsidiaries and the reports of the Directors and auditor eyear ended December 31, 2021. 506,226,597 (100.000000%)					
2.	(a)	To re-elect the following retiring Directors:					
		(i)	Dr. Zhaopeng HU as an executive Director	506,207,596 (99.996247%)	19,001 (0.003753%)		
		(ii)	Mr. Yanling CAO as a non-executive Director	505,940,096 (99.943405%)	286,501 (0.056595%)		
		(iii)	Mr. Yiran HUANG as an independent non-executive Director	487,865,097 (96.372869%)	18,361,500 (3.627131%)		
		(iv)	Mr. Zhenyu ZHANG as an independent non-executive Director	503,727,097 (99.506249%)	2,499,500 (0.493751%)		
	(b)	To authorise the Board of the Company to fix the remuneration of the Directors.		506,226,597 (100.000000%)	0 (0.000000%)		

		Ordinary Resolutions	Number of Votes (%)	
		Ordinary Resolutions	For	Against
3.		-appoint Deloitte Touche Tohmatsu as the auditor of the Company and rise the Board to fix their remuneration.	506,226,597 (100.000000%)	0 (0.000000%)
4.	(A)	To give a general mandate to the Directors to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the Company as of the date of this resolution.	451,422,476 (89.173994%)	54,804,121 (10.826006%)
	(B)	To give a general mandate to the Directors to repurchase shares not exceeding 10% of the issued share capital of the Company as of the date of this resolution.	506,226,597 (100.000000%)	0 (0.000000%)
	(C)	To extend the authority given to the Directors pursuant to ordinary resolution no. 4(A) to issue shares by adding to the issued share capital of the Company the number of shares repurchased under ordinary resolution no. 4(B).	434,850,476 (85.900361%)	71,376,121 (14.099639%)

Please refer to the Notice for the full text of the resolutions proposed at the Annual General Meeting.

As more than 50% of the votes were cast in favour of each of the above resolutions, all the resolutions were passed as ordinary resolutions at the Annual General Meeting.

The total number of issued Shares as of the date of the Annual General Meeting was 667,539,195 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all resolutions. There were no Shares entitling the holders to attend and abstain from voting in favor at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules. There were no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Annual General Meeting. No Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the Annual General Meeting and no Shareholder has stated his/her/its intention in the Circular to vote against or to abstain from voting the resolutions proposed at the Annual General Meeting.

The executive directors of the Company, Mr. Ye LIU and Dr. Zhaopeng HU, the non-executive directors of the Company, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG and the independent non-executive directors of the Company, Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG attended the Annual General Meeting, either in person or by means of telecommunication.

Computershare Hong Kong Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, acted as the scrutineer for counting of votes at the Annual General Meeting.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, June 24, 2022

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.